<?xml version="1.0" encoding="UTF-8"?>
<p>Similarly, BPG administration is painful and often leads to poor compliance—this is due to the higher injection volume (1.6–2.3 mL per injection), viscosity (due to high concentration of suspended BPG particles), and irritant nature of the suspension (leading to injection site reaction, such as pain, inflammation, erythema, swelling, and skin ulcer) [
 <xref rid="B39-antibiotics-09-00909" ref-type="bibr">39</xref>,
 <xref rid="B73-antibiotics-09-00909" ref-type="bibr">73</xref>,
 <xref rid="B74-antibiotics-09-00909" ref-type="bibr">74</xref>]. In addition, in case of recurrent impetigo infection, the fear of painful injection may result in needle phobia and non-compliance with the therapy [
 <xref rid="B74-antibiotics-09-00909" ref-type="bibr">74</xref>]. This shows that the current impetigo treatment options for Indigenous impetigo patients seem far more challenging that it often results in suboptimal clinical outcomes.
</p>
